Education
About Us
Working with TipRanks
Follow Us
Humacyte (HUMA)
:HUMA
HUMA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.15 - $9.97
Previous CloseN/A
Volume1.64M
Average Volume (3M)5.03M
Market Cap
$237.33M
Enterprise Value$676.68M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.68
Next Earnings
May 09, 2025EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.26
Shares Outstanding155,118,820
10 Day Avg. Volume6,883,114
30 Day Avg. Volume5,029,801
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.60
P/FCF Ratio0.00
Enterprise Value/Market Cap2.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-8.84
Enterprise Value/Ebitda-5.17
Forecast
1Y Price Target
$14.00Price Target Upside815.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Bulls Say, Bears Say
Bulls Say
Capital RaisingCapital Raise Will Help Fund the Symvess Launch and Development of Longer-Term Pipeline Opportunities: HUMA completed a public offering which will provide the company with $50M in gross proceeds.
Commercial LaunchHUMA's early Symvess launch progress is encouraging, and management has solid visibility into the 2025 revenue trajectory.
Market OpportunityThe recent pullback in HUMA shares is seen as a compelling buying opportunity for long-term focused investors.
Bears Say
Stock PressureHUMA stock pressure is overdone as a recent news article discussing Symvess' safety profile is 'old news' for investors and clinicians.
Stock ValuationPT moves to $5 from $7.50, to reflect the recent contraction in small-cap valuations and the new share.
---
Ownership Overview
5.94% Insiders
6.16% Mutual Funds
5.90% Other Institutional Investors
71.51% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HUMA FAQ
What was Humacyte’s price range in the past 12 months?
Humacyte lowest stock price was $1.15 and its highest was $9.97 in the past 12 months.
What is Humacyte’s market cap?
Humacyte’s market cap is $237.33M.
When is Humacyte’s upcoming earnings report date?
Humacyte’s upcoming earnings report date is May 09, 2025 which is in 25 days.
How were Humacyte’s earnings last quarter?
Humacyte released its earnings results on Mar 28, 2025. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.25 by $0.09.
Is Humacyte overvalued?
According to Wall Street analysts Humacyte’s price is currently Undervalued.
Does Humacyte pay dividends?
Humacyte does not currently pay dividends.
What is Humacyte’s EPS estimate?
Humacyte’s EPS estimate is -0.2.
How many shares outstanding does Humacyte have?
Humacyte has 155,118,820 shares outstanding.
What happened to Humacyte’s price movement after its last earnings report?
Humacyte reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.25. Following the earnings report the stock price went down -2.488%.
Which hedge fund is a major shareholder of Humacyte?
Currently, no hedge funds are holding shares in HUMA
---
Humacyte Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.00 (815.03% Upside)
$14.00 (815.03% Upside)
Blogger Sentiment
Bullish
HUMA Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $93.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.33%
12-Months-Change
Fundamentals
Return on Equity
239.90%
Trailing 12-Months
Asset Growth
7.53%
Trailing 12-Months
Company Description
Humacyte
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
---
HUMA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted significant achievements such as the FDA approval and successful launch of Symvess, as well as progress in the ATEV program. However, financial challenges remain with no revenue reported for 2024 and increased net losses. The sentiment reflects a balanced view of optimism for future growth and ongoing financial hurdles.Read More>---
HUMA Stock 12 Month Forecast
Average Price Target
$14.00
▲(815.03% Upside)
Technical Analysis
Vanda
―
Palvella Therapeutics
―
Atea Pharmaceuticals
―
Compass Therapeutics
―
Candel Therapeutics
―
Best Analysts Covering HUMA
1 Year
1 Year Success Rate
9/23 ratings generated profit
1 Year Average Return
-14.33%
reiterated a buy rating 17 days ago
Copying Ryan Zimmerman's trades and holding each position for 1 Year would result in 39.13% of your transactions generating a profit, with an average return of -14.33% per trade.
---